veliparib

Known as: 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide, 2-(2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide, (2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium 
A poly(ADP-ribose) polymerase (PARP) -1 and -2 inhibitor with chemosensitizing and antitumor activities. With no antiproliferative effects as a… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2018
010203020022018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
BACKGROUND The genetic and clinical heterogeneity of breast cancer makes the identification of effective therapies challenging… (More)
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2015
2015
BACKGROUND Veliparib is a potent small molecule inhibitor of PARP-1/2, which is cytotoxic in tumor cells with deficiencies in… (More)
Is this relevant?
2015
2015
PURPOSE Veliparib, a PARP inhibitor, demonstrated clinical activity in combination with oral cyclophosphamide in patients with… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2014
2014
Androgen receptor-mediated transcription is directly coupled with the induction of DNA damage, and castration-resistant tumor… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2014
2014
BACKGROUND AND OBJECTIVE Veliparib (ABT-888) is a potent oral inhibitor of Poly(ADP-ribose) polymerase enzyme that is currently… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
PURPOSE PARP1/2 inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair. Here, we describe… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Small-molecule inhibitors of PARP are thought to mediate their antitumor effects as catalytic inhibitors that block repair of DNA… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE Oral administration of the alkylating agent cyclophosphamide at low doses, metronomic dosing, is well tolerated, with… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE Poly(ADP-ribose) polymerase (PARP) inhibitors are undergoing extensive clinical testing for their single-agent activity… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
A phase I trial of ABT-888 (veliparib), a PARP inhibitor, in combination with topotecan, a topoisomerase I-targeted agent, was… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?